Search results for "SECO"

showing 10 items of 4119 documents

The Interaction of Buccal Mucosal Epithelial Cells with E. coli Bacteria Enhances the Intraepithelial Calcium Flux and the Release of Prostaglandin E…

1999

Mucosal epithelial cells contribute significantly to host defense mechanisms. Uroepithelial cells (UEC) from healthy donors suppress bacterial growth in vitro. Bacterial adherence to UEC has been shown to be a prerequisite. Similar results have been shown for buccal epithelial cells (BEC). The host response triggered by the host-parasite interaction seems to involve signal transduction and intracellular activation of second messengers. In this study the intraepithelial calcium flux was analyzed in individual BEC after bacterial contact. BEC were derived from scrapes of the buccal mucosa and labelled with fluo-3 (a calcium indicator). Thereafter the cells were analyzed immediately with a FAC…

AdultMaleUrologychemistry.chemical_elementCalciumBacterial AdhesionDinoprostoneCalcium in biologyMicrobiologychemistry.chemical_compoundMale Urogenital DiseasesCalcium fluxEscherichia coliHumansMedicineSecretionEscherichia coli Infectionsbusiness.industryMouth MucosaObstetrics and GynecologyEpithelial CellsMolecular biologyFemale Urogenital DiseaseschemistrySecond messenger systemFemaleCalcium ChannelsCell activationbusinessIntracellularHistamineSignal TransductionInternational Urogynecology Journal and Pelvic Floor Dysfunction
researchProduct

Visual tracking combined with hand-tracking improves time perception of moving stimuli

2014

A number of studies have shown that performing a secondary task while executing a time-judgment task impairs performance on the latter task. However, this turns out not to be the case for certain motor secondary tasks. We show that concomitant secondary motor tasks involving pointing, when performed during a time-judgment task, can actually improve our time-judgment abilities. We compared adult participants' performance in a time-of-movement paradigm with visual pursuit-only and with visual pursuit plus hand pursuit. Rather than interfering with their estimation of stimulus movement duration, the addition of hand pursuit significantly improved their judgment. In addition, we considered the …

AdultMalegenetic structuresSecondary taskMovementSpeech recognitionDecision MakingMotion PerceptionStimulus (physiology)Sensitivity and Specificitybehavioral disciplines and activitiesArticleVisual pursuitHumansMedicineMotion perceptionSimulationMultidisciplinarybusiness.industryReproducibility of ResultsTime perceptionTime PerceptionEye trackingFemaleCuesbusinessPhotic StimulationPsychomotor PerformanceScientific Reports
researchProduct

A double-blind study comparing paroxetine and maprotiline in depressed outpatients.

1997

A double-blind multicenter randomized parallel group study comparing paroxetine and maprotiline was carried out in a total of 544 outpatients. Included were patients with varying degrees of severity of depressive symptoms who fulfilled modified RDC criteria for either Minor or Major Depression and showed a HAMD-17 score of > or = 13. No concomitant benzodiazepine treatment was allowed. Duration of treatment was 6 weeks, after an initial wash-out period. Doses were fixed during the first 3 weeks of treatment, patients receiving either 20 mg paroxetine or 100 mg maprotiline daily. An option for dose escalation was provided for insufficient responders after 3 weeks. The weekly assessments comp…

AdultMalemedicine.drug_classDouble-Blind MethodAnticholinergicAmbulatory CareMedicineHumansPharmacology (medical)Adverse effectMaprotilinePsychiatric Status Rating ScalesBenzodiazepineDepressive Disorderbusiness.industryGeneral MedicineParoxetinePsychiatry and Mental healthParoxetineMaprotilineConcomitantAnesthesiaAntidepressantAntidepressive Agents Second-GenerationFemalebusinessReuptake inhibitormedicine.drugPharmacopsychiatry
researchProduct

Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit.

2012

Background: Corticosteroids are effective in the treatment of Crohn's disease but some patients relapse during tapering or after discontinuation. We report data on efficacy and prognostic factors of response of adalimumab in steroid-dependent patients. Methods: In all, 110 steroid-dependent patients were treated with adalimumab (80/40 or 160/80 mg every other week followed by 40 mg every other week). Clinical remission was defined as steroid discontinuation without symptomatic recurrence and clinical response as the reduction or maintenance of the initial Crohn's Disease Activity Index (CDAI) value reducing steroid dosage but without its discontinuation at week 6 and at the end of follow-up…

AdultMalemedicine.medical_specialtyAdolescentAnti-Inflammatory AgentsAntibodies Monoclonal HumanizedInflammatory bowel diseaseYoung AdultCrohn DiseaseInternal medicinemedicineAdalimumabSecondary PreventionImmunology and AllergyHumansProspective StudiesYoung adultProspective cohort studyGlucocorticoidsAgedUnivariate analysisCrohn's diseasebusiness.industryRemission InductionGastroenterologyAdalimumabMiddle Agedmedicine.diseasePrognosisSurgeryDiscontinuationRegimenFemalebusinessmedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct

Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial

2015

Patients with Major Depressive Disorder (MDD) and no improvement after two weeks of antidepressant pharmacotherapy have a high risk of treatment failure. The aim of the study was to determine whether an early medication change (EMC) strategy is superior to a guideline-based treatment in MDD patients without improvement after two weeks of antidepressant pharmacotherapy. Eight-hundred-and-eighty-nine patients with MDD were enrolled, 879 patients received the SSRI escitalopram. Of those, 192 patients had no improvement, defined as a reduction of < 20% on the Hamilton Depression Rating Scale (HAMD-17) after 14 days of treatment, and were randomly assigned to open treatment with the EMC strategy…

AdultMalemedicine.medical_specialtyAdolescentCitalopramLithiumCitalopramlaw.inventionDepressive Disorder Treatment-ResistantYoung Adult03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled triallawEarly Medical InterventionInternal medicinemedicineHumansEscitalopramPharmacology (medical)PsychiatryBiological PsychiatryAgedPharmacologyVenlafaxine HydrochlorideGuidelineMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryClinical trialPsychiatry and Mental healthTreatment OutcomeNeurologyDelayed-Action PreparationsAntidepressive Agents Second-GenerationAntidepressantMajor depressive disorderDrug Therapy CombinationFemaleNeurology (clinical)Psychology030217 neurology & neurosurgerymedicine.drugEuropean Neuropsychopharmacology
researchProduct

Evaluation of the Possible Impact of a Care Network for Stroke and Transient Ischemic Attack on Rates of Recurrence

2010

We aimed to demonstrate that a stroke network is able to reduce the proportion of recurrent cerebrovascular events. In 2003, we set up a care network with the aim to reduce the proportion of stroke recurrence. For the statistical analysis, recurrent cerebrovascular events observed from 1985 to 2002 within the population of Dijon made it possible to model trends using Poisson logistic regression. From 1985 to 2002, we recorded 172 recurrent cerebrovascular events which were used to model trends before the creation of the care network. Within the period 2003–2007, we observed 162 recurrent cerebrovascular events compared with 196.7 expected cerebrovascular events with a significant standardiz…

AdultMalemedicine.medical_specialtyAdolescentCommunity NetworksYoung AdultSecondary PreventionHumansMedicineTransient (computer programming)cardiovascular diseasesChildStrokeAgedAged 80 and overbusiness.industryInfant NewbornInfantMiddle Agedmedicine.diseaseStrokeNeurologyIschemic Attack TransientChild PreschoolEmergency medicinePhysical therapyFemaleFranceNeurology (clinical)businessEuropean Neurology
researchProduct

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

2012

BACKGROUND: Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. METHODS: We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophil…

AdultMalemedicine.medical_specialtyAdolescentPlacebo-controlled studyFevipiprantAntibodies Monoclonal HumanizedPlaceboLebrikizumabDrug Administration ScheduleLeukocyte CountYoung Adultchemistry.chemical_compoundDouble-Blind MethodReslizumabInternal medicineSecondary PreventionmedicineHumansAnti-Asthmatic AgentsPulmonary EosinophiliaChildGlucocorticoidsAgedAsthmaDose-Response Relationship Drugbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseBenralizumabAsthmaEosinophilsTreatment OutcomechemistryPhysical therapyDrug Therapy CombinationFemaleInterleukin-5businessMepolizumabmedicine.drugThe Lancet
researchProduct

The Effect of Age, Sex, Smoking and Co-Medication on Serum Levels of Venlafaxine and O-Desmethylvenlafaxine under Naturalistic Conditions

2012

Venlafaxine (VEN) is a modern antidepressant which exerts both serotonin and norepinephrine reuptake inhibition. In this study we examined the influence of age, sex, smoking, and co-medication on serum levels of VEN and its metabolite O-desmethylvenlafaxine (ODVEN) in patients treated with VEN under naturalistic conditions.We retrospectively evaluated 478 TDM analyses of VEN requested in the Pychiatric University Hospitals of Mainz, Regensburg, and Würzburg. The determination of serum levels was performed by virtually identical chromatographic methods in the TDM laboratories of the participating hospitals.Serum levels varied widely on each dose level. Women had about 30% higher dose-correct…

AdultMalemedicine.medical_specialtyAdolescentVenlafaxine HydrochlorideVenlafaxinePharmacokineticsDesvenlafaxine SuccinateInternal medicinemedicineHumansPharmacology (medical)DosingAgedRetrospective StudiesAged 80 and overSex Characteristicsbusiness.industrySmokingAge FactorsVenlafaxine HydrochlorideRetrospective cohort studyGeneral MedicineMiddle AgedCyclohexanolsPsychiatry and Mental healthAnesthesiaVenAntidepressive Agents Second-GenerationAntidepressantDrug Therapy CombinationFemaleDrug Monitoringbusinessmedicine.drugSex characteristicsPharmacopsychiatry
researchProduct

Left ventricular mass in hypertensive patients with mild-to-moderate reduction of renal function

2010

Aim: Left ventricular hypertrophy (LVH) is an independent predictor of cardiovascular (CV) morbidity and mortality. The aim of the present study was to evaluate the relationship between LV mass and mild-to-moderate renal dysfunction in a group of non-diabetic hypertensives, free of CV diseases, participating in the Renal Dysfunction in Hypertension (REDHY) study. Methods: Patients with diabetes, a body mass index (BMI) of more than 35 kg/m 2 , secondary hypertension, CV diseases and a glomerular filtration rate (GFR) of less than 30 mL/min per 1.73 m 2 were excluded. The final sample included 455 patients, who underwent echocardiographic examination and ambulatory blood pressure monitoring.…

AdultMalemedicine.medical_specialtyAmbulatory blood pressureBody Surface AreaHeart VentriclesPopulationSecondary hypertensionRenal functionBlood PressureKidneyurologic and male genital diseasesLeft ventricular hypertrophyRisk AssessmentSeverity of Illness IndexRisk FactorsInternal medicinemedicineHumansHypertension Glomerular filtration rate Chronic kidney disease Cardiovascular disease Left ventricular mass Left ventricular hypertrophy.educationBody surface areaeducation.field_of_studyChi-Square Distributionbusiness.industryConfounding Factors EpidemiologicGeneral MedicineBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseaseBody HeightCross-Sectional StudiesLogistic ModelsBlood pressureItalyEchocardiographyNephrologyHypertensionCardiologyFemaleHypertrophy Left VentricularKidney DiseasesbusinessGlomerular Filtration RateKidney diseaseNephrology
researchProduct

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.

2006

SUMMARY Background: Venlafaxine (V) is a mixed serotoninand noradrenaline reuptake inhibitor used as afirst-line treatment of depressive disorders. It ismetabolized primarily by the highly polymorphiccytochrome P450 (CYP) enzyme CYP2D6 to yielda pharmacologically active metabolite, O-des-methylvenlafaxine (ODV), and to a lesser extentby CYP3A4, to yield N-desmethylvenlafaxine(NDV).Objectives: The aim of this study was to assesswhether the O-demethylation phenotype of V hasan impact on the pharmacokinetics and clinicaloutcome.Method: In 100 patients treated with V, serumconcentrations of V, ODV and NDV and theratios of concentrations ODV/V as a measure ofO-demethylation were determined. Indiv…

AdultMalemedicine.medical_specialtyCYP2D6AdolescentGenotypeVenlafaxine HydrochlorideVenlafaxineBiology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineDesvenlafaxine SuccinateGenotypemedicineHumansPharmacology (medical)Active metaboliteAgedPharmacologyDepressive DisorderPolymorphism GeneticfungiVenlafaxine HydrochlorideMiddle AgedCyclohexanols3. Good healthEndocrinologyCytochrome P-450 CYP2D6PharmacogeneticsAntidepressive Agents Second-GenerationFemaleReuptake inhibitor030217 neurology & neurosurgeryPharmacogeneticsmedicine.drugJournal of clinical pharmacy and therapeutics
researchProduct